Dupilumab Market Size and Forecast Through 2034
DelveInsight has released a market analysis and forecast for Dupilumab, projecting its market size through 2034. The report details the drug's growth across multiple therapeutic areas.
Market research firm DelveInsight has published a report analyzing the market size and forecast for Dupilumab through 2034. The report focuses on the drug's sales and growth, particularly following its approval for treating Chronic Obstructive Pulmonary Disease (COPD).
Dupilumab, developed by Sanofi and Regeneron Pharmaceuticals, achieved global sales of €10.7 billion in 2023, representing a 31% year-over-year increase. Sales in Q2 2025 reached $4.34 billion, indicating continued momentum. The COPD approval, initially in September 2024 and subsequently in the EU, China, and Japan in 2025, is cited as a significant growth driver.
The report highlights Dupilumab's broad application across various conditions, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and chronic spontaneous urticaria. The US approval in April 2025 for treating chronic spontaneous urticaria in pediatric patients further solidified its market position.
According to DelveInsight's analysis, Dupilumab's strong performance in comparative studies against competitors like Xolair is expected to enhance its market share retention. The firm anticipates continued robust sales for Dupilumab in the coming years, supported by its diverse indications and ongoing research and development efforts.